Mounjaro, EU and Lilly

EU drugs regulator backs Mounjaro's sleep apnea use without fresh approval for Lilly
The European Medicines Agency has allowed Eli Lilly to update the product label of its weight-loss drug Mounjaro to show it has benefit in treating a sleep disorder without approving it specifically for the disease,
Eli Lilly’s Mounjaro Won’t Have Separate Sleep Apnea Label in EU
Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with regulators saying Friday that use of the drug is already covered in its approval as a weight-loss medicine.
Lilly's Mounjaro does not need separate indication for sleep apnea, EMA panel determines
An expert panel of the EU drug regulator, the European Medicines Agency (EMA), has determined that Eli Lilly's (NYSE:LLY) weight-loss drug Mounjaro (tirzepatide) does not need a separate indication for the treatment of obstructive sleep apnea (OSA).
EMA says Lilly's weight-loss drug does not need separate approval for sleep apnea
The European Medicines Agency said on Friday Eli Lilly's weight-loss drug Mounjaro does not need a separate approval for the treatment of a sleep disorder called obstructive sleep apnea (OSA). The hea
Eli Lilly to test weight loss drug Zepbound to treat addiction
Weight loss injections have become a popular choice to help people curb their appetite, but can they curb addiction, as well?
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...
Lilly CEO says tax and regulation reform, drug affordability are focuses under Trump
Eli Lilly CEO David Ricks on Tuesday said at the Economic Club of Washington that tax and regulation reform and drug ...
STAT4d
Eli Lilly strikes Zepbound deal with Ro, amid questions about future of compounded GLP-1s
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
Eli Lilly Stock Could Have a Huge Growth Catalyst in Early 2025
Eli Lilly ( LLY -1.72%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...
RFK Jr. on Ozempic, Eli Lilly's next test, and Elon Musk gets on the bandwagon: Pharma news roundup
Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...
Verywell Health on MSN1d
Zepbound Helps People Shed More Weight Than Wegovy, According to Eli Lilly Trial
Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...
Fierce Healthcare3d
Ro teams up with Eli Lilly to offer single-dose vials of weight loss drug Zepbound
Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...
Ripley County Lilly Scholar announced
The Ripley County Community Foundation has announced the recipient of the 2025 Lilly Endowment Community Scholarship for ...
How new 'IU LAB' will reshape Indianapolis' 16 Tech district after $138 million Lilly grant
A six-floor, 150,000-square-foot facility will serve as IU's home in the 50-acre 16 Tech campus, where Purdue has also ...
Lilly's Mounjaro more popular than Wegovy in UK's private obesity drug market
Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online ...